Drug Price Trends for NDC 65145-0161

Average Pharmacy Cost for 65145-0161

Drug Name	NDC	Price/Unit ($)	Unit	Date
DIFLUPREDNATE 0.05% EYE DROP	65145-0161-01	9.58196	ML	2026-03-18
DIFLUPREDNATE 0.05% EYE DROP	65145-0161-01	9.78583	ML	2026-02-18
DIFLUPREDNATE 0.05% EYE DROP	65145-0161-01	10.45989	ML	2026-01-21
DIFLUPREDNATE 0.05% EYE DROP	65145-0161-01	10.24834	ML	2025-12-17

Best Wholesale Price for NDC 65145-0161

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Novo Nordisk's Ozempic (semaglutide) Price Trajectory and Market Dominance Analysis

Last updated: February 19, 2026

This analysis examines the current market position and projected price evolution for Novo Nordisk’s Ozempic (semaglutide) in the United States. The drug’s established efficacy in managing type 2 diabetes, coupled with its growing off-label use for weight management, underpins its market strength. Pricing strategies, driven by patent protection, payer negotiations, and competitive pressures, will be a critical determinant of future revenue.

What is Ozempic and Its Therapeutic Applications?

Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. Its primary approved indication is for the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise, to improve glycemic control. Clinical studies have demonstrated significant reductions in glycated hemoglobin (HbA1c) levels and cardiovascular risk factors in this patient population.

Beyond its approved indication, Ozempic has gained substantial traction for weight management. Real-world data and clinical trials, such as the STEP program (Semaglutide Treatment to lower BMI, Cardiovascular, and other Outcomes), have shown significant and sustained weight loss in individuals with obesity or overweight, irrespective of diabetes status. This off-label use is a major driver of demand and market expansion.

The active pharmaceutical ingredient (API) is semaglutide, a peptide analog that mimics the action of the natural incretin hormone GLP-1. It works by stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.

What is the Current Market Share and Competitive Landscape for Ozempic?

Ozempic holds a dominant position in the GLP-1 receptor agonist market for type 2 diabetes. As of the first quarter of 2024, Novo Nordisk reported global sales of Ozempic to be DKK 14.9 billion (approximately $2.2 billion USD), highlighting its significant market penetration [1].

The competitive landscape for GLP-1 receptor agonists is intensifying, with several key players vying for market share. Major competitors include:

• Eli Lilly and Company: With tirzepatide (Mounjaro for diabetes, Zepbound for weight management), a dual GIP and GLP-1 receptor agonist, offering potentially greater efficacy in both glycemic control and weight loss.
• AstraZeneca: With exenatide (Bydureon BCise) and liraglutide (Victoza).
• Takeda Pharmaceutical Company: With exenatide (Byetta).
• Pfizer: Developing oral semaglutide (danuglipron) and other oral GLP-1 receptor agonists, which, if approved, could disrupt the market by offering alternative delivery methods.

Despite the emergence of potent competitors like tirzepatide, Ozempic maintains a strong foothold due to its established safety profile, extensive clinical data, and broad prescriber familiarity. Its effectiveness in diabetes management, coupled with its growing role in weight management, solidifies its market leadership.

What are the Key Patents Protecting Ozempic and When Do They Expire?

Novo Nordisk holds a robust portfolio of patents protecting semaglutide and its various formulations and methods of use. The primary patent protection for the semaglutide molecule itself is critical.

Key patent families for semaglutide include those covering the chemical composition of matter, manufacturing processes, and specific formulations designed for optimal delivery and efficacy. While specific patent expiry dates are subject to ongoing litigation and patent office decisions, general timelines indicate substantial market exclusivity for Novo Nordisk.

• Composition of Matter Patents: These are generally the strongest and longest-lasting patents. For semaglutide, the core composition of matter patents are anticipated to expire in the mid-to-late 2030s. For example, U.S. Patent No. 9,987,434, which covers certain semaglutide compounds, is expected to expire around 2031, with potential for patent term extensions.
• Formulation and Method of Use Patents: Novo Nordisk also holds patents on specific drug delivery systems (e.g., injection devices) and methods of treating diabetes and obesity with semaglutide. These patents can provide additional layers of protection and extend market exclusivity for specific applications or delivery methods. These can expire at various points, some as early as the late 2020s, but their expiry does not necessarily open the door for direct generic competition to the core molecule.
• Pediatric Exclusivity: For drugs approved with pediatric studies, an additional six months of market exclusivity is granted. While specific details for Ozempic's pediatric studies and their associated exclusivity timelines are proprietary, this can further extend protection.

It is crucial to note that patent landscapes are dynamic. Novo Nordisk actively defends its intellectual property, and challenges from generic manufacturers are common. Litigation surrounding patent validity and infringement can significantly alter these expiry dates. The potential for biosimilar or generic entry will heavily depend on the ability of competitors to design around existing patents or successfully invalidate them.

What is the Current Pricing Structure for Ozempic in the US?

The United States exhibits one of the highest pharmaceutical pricing structures globally. Ozempic's pricing reflects this reality, influenced by list prices, net prices after rebates, and the value proposition it offers in managing chronic conditions.

The Wholesale Acquisition Cost (WAC), or list price, for Ozempic varies by dosage and pen size. As of early 2024, typical WACs for a 4-week supply (four 0.5 mg pens) of Ozempic fall within the range of $900 to $1,000 USD. For higher dosages, such as the 2.0 mg pens, the WAC can exceed $1,100 USD for a 4-week supply.

However, the WAC is rarely the actual price paid by payers or patients. Net prices are significantly lower due to substantial rebates and discounts negotiated with pharmacy benefit managers (PBMs) and insurance providers. These rebates are often undisclosed and constitute a significant portion of the drug's commercial price.

• Dosage: 0.25 mg, 0.5 mg, 1 mg, 2 mg
• Pen Size: Typically four pens per pack, providing a 4-week supply.
• Estimated Net Price Range: While precise net prices are confidential, industry estimates suggest net prices can be 30-60% lower than WAC, depending on the payer contract and volume. This can place the effective net cost to payers in the range of $400 to $700 USD per month for standard dosages.

The out-of-pocket cost for patients depends heavily on their insurance plan, deductible, copay, and coinsurance. Many patients with robust insurance coverage face copays in the range of $20 to $100 USD per month. However, uninsured or underinsured patients can face substantial costs, leading to financial burdens and potential access challenges.

What are the Projected Price Trends for Ozempic in the US?

Projected price trends for Ozempic are influenced by several intersecting factors:

1. Patent Exclusivity: The extended patent life for semaglutide's composition of matter provides Novo Nordisk with a significant period of market exclusivity. This allows for sustained pricing power without direct generic competition for the core molecule.
2. Demand and Utilization: The escalating demand, driven by both its approved indication for type 2 diabetes and its off-label use for weight management, supports current pricing levels and creates pressure for price increases. The substantial unmet need in obesity treatment further amplifies this demand.
3. Payer Negotiations and Rebates: While list prices may increase incrementally year-over-year, the actual net price realized by Novo Nordisk will continue to be shaped by aggressive rebate negotiations with payers. PBMs wield significant leverage, demanding discounts in exchange for favorable formulary placement.
4. Competitive Pressures: The introduction of new and potentially more effective GLP-1 RAs and dual agonists (like tirzepatide) by competitors creates a dynamic pricing environment. Novo Nordisk may need to adjust pricing or offer more aggressive rebates to maintain market share against these newer entrants, particularly in the weight-loss segment.
5. Regulatory and Political Factors: Increased scrutiny on drug pricing by policymakers and the public could lead to greater pressure for price reductions or more transparency. However, the pharmaceutical industry has historically shown resilience to significant pricing reforms in the U.S. market.

Price Projection Scenarios:

• Scenario 1: Modest Incremental Increases (Most Likely): Novo Nordisk will likely continue to implement annual list price increases, typically in the 3-7% range, aligning with historical industry practices. Net prices may see smaller fluctuations, as rebates adapt to offset list price hikes. This scenario is supported by ongoing demand and continued patent protection.
• Scenario 2: Price Moderation Due to Competition: If competitors like Eli Lilly’s tirzepatide gain substantial market share in both diabetes and weight management, Novo Nordisk might face pressure to moderate price increases or offer more competitive net pricing to retain market share. This could lead to net price growth being below list price increases.
• Scenario 3: Significant Price Reductions (Least Likely): Without substantial changes in the regulatory environment or overwhelming competitive disruption, significant price reductions are improbable while Ozempic maintains its exclusivity.

Overall Projection: Expect continued annual list price increases. The effective net price may see slower growth or stabilization as rebate structures adapt to market dynamics. The average net price per unit is projected to remain strong throughout the patent-protected period, likely staying in the $400-$800 USD range per month for typical therapy, with potential for slight increases over the next five years, assuming no major disruptive events.

What is the Expected Impact of Potential Generic or Biosimilar Entry?

The potential entry of generic or biosimilar semaglutide is a critical factor for future pricing. The timeline for such entry is directly tied to the expiry of Ozempic's core patents.

• Target Entry Timeline: Based on current patent expiry estimates for the composition of matter patents (mid-to-late 2030s), generic or biosimilar semaglutide is unlikely to enter the US market in significant numbers before 2032-2035.
• Impact on Pricing: Upon the first generic or biosimilar entry, significant price erosion is expected. Historically, generic drug prices can fall by 70-90% within months of market entry, driven by competition and the lower cost structures of generic manufacturers. Biosimilar pricing for biologics has seen a more varied impact, with initial discounts typically ranging from 15-35% compared to the originator biologic, although this gap can widen over time.
• Market Dynamics: The availability of generics/biosimilars will likely lead to:
  • Increased Affordability: Lower prices would expand access for patients and payers.
  • Market Share Shift: Generic/biosimilar manufacturers will aggressively compete, potentially capturing a substantial portion of the market.
  • Novo Nordisk's Strategy: Novo Nordisk will likely leverage its follow-on products, such as oral semaglutide (Rybelsus) or next-generation GLP-1 RAs, to retain market share and transition patients. They may also engage in aggressive defense of their intellectual property.
• Challenges for Generic/Biosimilar Manufacturers:
  • Patent Litigation: Navigating extensive patent portfolios and potential litigation.
  • Manufacturing Complexity: Semaglutide is a complex peptide requiring specialized manufacturing capabilities.
  • Regulatory Hurdles: Obtaining FDA approval for generics and biosimilars involves rigorous testing and demonstration of bioequivalence or biosimilarity.

The exact impact will depend on the number of competitors entering the market, their pricing strategies, and the specific patents they are able to circumvent or challenge. However, a substantial price decline for semaglutide is inevitable once effective patent protection lapses.

Key Takeaways

• Ozempic (semaglutide) is a dominant GLP-1 RA in the US type 2 diabetes market, with significant growth driven by off-label weight management use.
• Novo Nordisk benefits from strong patent protection for semaglutide, with core composition of matter patents expiring in the mid-to-late 2030s.
• Current US pricing shows high list prices ($900-$1,100+ per month) significantly offset by confidential rebates, resulting in estimated net prices of $400-$700 per month.
• Price projections indicate continued annual list price increases (3-7%), with net price growth likely moderated by competitive pressures and payer negotiations.
• Significant price erosion is anticipated upon the entry of generic or biosimilar semaglutide, estimated for the mid-2030s, with potential price drops of 70-90% for generics and 15-35%+ for biosimilars.

Frequently Asked Questions

1. What is the primary driver of Ozempic's current market dominance? Ozempic's market dominance is primarily driven by its proven efficacy in managing type 2 diabetes, coupled with a substantial and growing demand for its off-label use in weight management, supported by extensive clinical data.

2. How does the introduction of tirzepatide (Mounjaro/Zepbound) impact Ozempic's market position? Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents a significant competitive threat, potentially offering superior efficacy in both glycemic control and weight loss. This competition is expected to influence Novo Nordisk's pricing and market strategy.

3. Are there any immediate threats to Ozempic's patent exclusivity before the mid-2030s? While Novo Nordisk actively defends its intellectual property, ongoing patent litigation and challenges from generic manufacturers represent potential, albeit uncertain, threats that could impact exclusivity timelines.

4. What is the projected impact of Ozempic's success on the development of other weight-loss medications? Ozempic's success has catalyzed significant investment and research into GLP-1 receptor agonists and other obesity pharmacotherapies, leading to a more robust pipeline of potential future treatments.

5. How does Novo Nordisk manage net pricing given the high list prices and rebate structures in the US? Novo Nordisk employs sophisticated pricing strategies, including negotiating substantial rebates with pharmacy benefit managers and payers in exchange for favorable formulary placement, which significantly lowers the effective net price of Ozempic.

Citations

[1] Novo Nordisk. (2024, May 2). Interim Report January – March 2024. Novo Nordisk Investor Relations.